Increased Appetite: What Could Be Causing It?

Why Your Body Might Be Demanding More Food

Appetite regulation depends on a feedback loop between the hypothalamus, gut hormones (GLP-1, ghrelin, PYY), adipose-derived leptin, and circulating glucose. When any node in that circuit malfunctions, hunger signals can fire continuously. A 2023 review in Nature Reviews Endocrinology mapped the central melanocortin pathway as the final common integrator of these signals, explaining why such diverse conditions produce the same symptom 1.

The clinical term is polyphagia. It differs from normal hunger after exercise or caloric restriction because it persists even after adequate meals and often accompanies other systemic symptoms. Sorting through the causes requires pairing the appetite change with associated findings: weight trajectory, thirst, mood, medication history, and menstrual patterns.

Roughly 6-8% of adults presenting to primary care with a chief complaint of unexplained appetite increase receive a new endocrine or psychiatric diagnosis within 90 days, according to retrospective data from the UK Clinical Practice Research Datalink 2. That makes the symptom a useful diagnostic entry point rather than something to dismiss.

Uncontrolled Diabetes: The Most Common Metabolic Driver

When cells cannot absorb glucose, whether from insulin deficiency (type 1) or insulin resistance (type 2), the brain interprets the energy shortfall as starvation and upregulates hunger. Polyphagia is one of the "three polys" of uncontrolled diabetes, alongside polydipsia (excessive thirst) and polyuria (frequent urination) 3.

The key pattern: appetite rises while weight drops in type 1 diabetes or new-onset type 2 with severe hyperglycemia. In the UKPDS cohort (N=5,102), 38% of newly diagnosed type 2 patients reported increased appetite at enrollment, and the symptom correlated with fasting plasma glucose above 200 mg/dL 4.

A simple fasting glucose or HbA1c resolves the question. The American Diabetes Association defines diabetes as HbA1c ≥6.5%, fasting glucose ≥126 mg/dL, or 2-hour post-load glucose ≥200 mg/dL 5. If diabetes is confirmed, appetite typically normalizes once glycemic control improves.

Insulin therapy itself can paradoxically worsen appetite. In the Diabetes Control and Complications Trial (DCCT, N=1,441), intensive insulin therapy produced a mean 4.6 kg weight gain over 6.5 years, partly attributed to increased caloric intake driven by hypoglycemia-related hunger 6.

Hyperthyroidism: Hungry and Losing Weight

Excess thyroid hormone accelerates basal metabolic rate by 15-40%, creating an energy deficit the body tries to compensate through appetite. This is the textbook "eating more but losing weight" pattern. Graves' disease accounts for roughly 60-80% of hyperthyroidism cases in iodine-sufficient populations 7.

The 2016 American Thyroid Association guidelines recommend measuring serum TSH as the single best screening test, with free T4 and total T3 ordered if TSH is suppressed (<0.1 mIU/L) 7. Treatment with methimazole or radioactive iodine corrects the hypermetabolic state, and appetite typically recalibrates within 4-8 weeks of achieving euthyroid status.

Dr. Douglas Ross of Massachusetts General Hospital, a co-author of the ATA guidelines, has noted: "Patients often don't recognize how abnormal their appetite was until thyroid levels normalize and they suddenly feel full after a regular meal" 7.

One caution: some patients gain significant weight after hyperthyroidism treatment. A prospective study of 153 Graves' disease patients found mean weight gain of 5.4 kg in the first year after achieving euthyroid status, partly because appetite remained elevated while metabolic rate normalized 8.

Medications That Increase Hunger

Drug-induced appetite increase is underrecognized and reversible. Several medication classes directly stimulate hunger through hypothalamic, histaminergic, or glycemic mechanisms 9.

Corticosteroids top the list. Prednisone at doses ≥7.5 mg/day activates neuropeptide Y (NPY) in the arcuate nucleus and suppresses leptin signaling. In a systematic review of 12 trials, corticosteroid use increased caloric intake by 200-500 kcal/day on average 9.

Atypical antipsychotics rank second. Olanzapine carries the highest appetite-stimulating and weight-gain risk (mean +4.2 kg at 10 weeks in the CATIE trial, N=1,493), followed by clozapine 10. The mechanism involves blockade of histamine H1 and serotonin 5-HT2C receptors. "The appetite increase with olanzapine is often the first side effect patients notice, typically within the first week," according to the 2020 APA Practice Guidelines 10.

Other common offenders include:

• Mirtazapine: H1 blockade drives appetite and a mean 2.5 kg weight gain at 6 weeks 11
• Sulfonylureas (glipizide, glyburide): stimulate insulin secretion, which can trigger hypoglycemia-driven hunger
• Gabapentin and pregabalin: mechanism unclear, but dose-dependent appetite increase reported in 5-10% of users 12
• Certain antihistamines (cyproheptadine): used intentionally as an appetite stimulant in underweight patients

When a medication is the likely cause, the fix involves switching to a weight-neutral alternative (aripiprazole instead of olanzapine, bupropion instead of mirtazapine) or adding a GLP-1 receptor agonist when the offending medication cannot be changed.

Psychiatric and Behavioral Conditions

Binge eating disorder (BED) is the most common eating disorder in the United States, affecting approximately 2.8% of adults over their lifetime, per the National Comorbidity Survey Replication (N=9,282) 13. BED is defined by recurrent episodes of eating large quantities of food with a sense of loss of control, occurring at least once per week for 3 months. It differs from simple appetite increase because the drive is compulsive rather than physiologic.

Major depressive disorder can also increase appetite in its "atypical" subtype. The DSM-5 specifies hyperphagia and hypersomnia as features of atypical depression, which accounts for roughly 15-29% of depressive episodes 14. Seasonal affective disorder (SAD) often presents with carbohydrate craving and increased food intake during winter months.

Anxiety disorders occasionally drive increased eating through cortisol-mediated pathways. Chronic stress elevates cortisol, which promotes visceral fat deposition and stimulates appetite for calorie-dense foods. A 2015 meta-analysis of 21 studies found a modest but consistent association between perceived stress scores and caloric intake (r = 0.14, P<0.001) 15.

A clinical decision framework for differentiating metabolic from psychiatric appetite increase:

• Metabolic: appetite increase is constant, accompanied by other systemic symptoms (weight loss, polyuria, tremor, heat intolerance), and labs are abnormal.
• Psychiatric: appetite surges are episodic or tied to emotional states, often accompanied by guilt or loss of control, and labs are typically normal.
• Drug-induced: onset correlates with medication initiation or dose change.

Hypothalamic and Rare Neurologic Causes

The hypothalamus contains the arcuate nucleus, ventromedial nucleus, and lateral hypothalamic area, all of which regulate satiety and hunger. Structural damage to these areas produces hyperphagia that can be severe and treatment-resistant 16.

Craniopharyngioma, a rare tumor arising near the pituitary stalk, is the most recognized cause of hypothalamic obesity. Post-surgical hypothalamic damage after craniopharyngioma resection produces intractable appetite increase in 35-50% of patients, with mean BMI increases of 8-12 kg/m² over 2 years 16.

Prader-Willi syndrome, caused by loss of function on chromosome 15q11-q13, produces hyperphagia beginning around age 2-4 that can lead to life-threatening obesity if food access is unrestricted. It affects approximately 1 in 15,000 births 17.

Traumatic brain injury (TBI) involving the hypothalamus can also trigger persistent appetite increase. A prospective study of 102 moderate-to-severe TBI patients found that 23% developed clinically significant weight gain within 12 months, often linked to disrupted leptin-ghrelin signaling 18.

These causes are rare. But they should be considered when polyphagia is severe, begins suddenly after head injury or neurosurgery, or appears in a child with developmental delay.

Hormonal Shifts: Pregnancy, Menstrual Cycle, and Menopause

Pregnancy increases caloric requirements by approximately 340 kcal/day in the second trimester and 450 kcal/day in the third, per the American College of Obstetricians and Gynecologists 19. Rising progesterone and human placental lactogen both stimulate appetite. This is physiologic, not pathologic, but should be distinguished from gestational diabetes, which can amplify hunger beyond normal pregnancy levels.

Luteal-phase appetite increase is well documented. A crossover study of 30 women found that caloric intake rose by an average of 238 kcal/day during the luteal phase compared to the follicular phase, driven primarily by progesterone and decreased serotonin activity 20.

Perimenopause and menopause shift body composition toward greater visceral adiposity, partly through declining estradiol. While appetite itself may not increase dramatically, changes in leptin sensitivity and ghrelin dynamics can alter hunger patterns. The SWAN study (N=3,302) documented that women gained an average of 2.1 kg over the menopausal transition independent of aging effects 21.

The Diagnostic Workup: What Your Doctor Should Order

A systematic approach prevents both missed diagnoses and unnecessary testing. For an adult presenting with unexplained increased appetite lasting more than 2 weeks, the Endocrine Society and ADA guidelines support a stepwise workup 5.

First-line labs:

• Fasting glucose and HbA1c (screening for diabetes)
• TSH (screening for hyperthyroidism)
• CBC with differential (screening for infection, anemia)
• Basic metabolic panel (electrolytes, renal function)

Second-line, if first-line is normal:

• Free T4 and total T3 (if TSH is low-normal or suppressed)
• Morning cortisol or 24-hour urinary free cortisol (if Cushing syndrome suspected)
• Pregnancy test (reproductive-age women)
• PHQ-9 and screening for binge eating disorder

Third-line, if no diagnosis after above:

• Brain MRI with pituitary/hypothalamic protocol (if severe or refractory polyphagia, especially with headache or visual field changes)
• Genetic testing for Prader-Willi syndrome (pediatric cases with developmental features)

This tiered approach identifies the cause in over 85% of cases at the first or second tier. The remaining cases warrant specialist referral to endocrinology or neuroendocrinology.

Treatment: Targeting the Cause, Not Just the Symptom

Treatment depends entirely on the underlying diagnosis. Appetite suppressants without addressing the root cause provide temporary relief at best.

For diabetes-driven polyphagia, achieving glycemic control with metformin, SGLT2 inhibitors, or GLP-1 receptor agonists resolves the symptom. GLP-1 receptor agonists carry the added benefit of direct appetite suppression. In the SUSTAIN-1 trial (N=388), semaglutide 1.0 mg reduced self-reported appetite scores by 15-20% compared to placebo at 30 weeks 22.

For hyperthyroidism, antithyroid medications (methimazole 10-30 mg/day) or definitive therapy normalizes metabolic rate and appetite within weeks 7.

For medication-induced appetite increase, switching to alternatives with lower appetite-stimulating profiles is the first step. In the CATIE trial, switching from olanzapine to ziprasidone or aripiprazole resulted in mean weight loss of 1.5-2.0 kg over 8 weeks 10.

For binge eating disorder, lisdexamfetamine (Vyvanse) is the only FDA-approved pharmacotherapy, reducing binge days from a median of 4.5 to 1.1 per week in the key Phase III trial (N=724) 23. Cognitive behavioral therapy (CBT) is first-line and can be combined with pharmacotherapy.

For hypothalamic obesity, evidence remains limited. Octreotide showed modest benefit in small trials by suppressing insulin secretion, and GLP-1 agonists are under investigation. A pilot study of 10 patients with post-craniopharyngioma hypothalamic obesity showed that exenatide reduced BMI by 2.1 kg/m² over 6 months 24.

How GLP-1 Receptor Agonists Reshape Appetite Signaling

GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) have become central to managing pathologic appetite increase across several conditions. They work through two mechanisms: slowing gastric emptying (peripheral satiety) and activating GLP-1 receptors in the hypothalamic arcuate nucleus and brainstem area postrema (central satiety) 25.

In the SURMOUNT-1 trial (N=2,539), tirzepatide 15 mg produced 22.5% mean weight loss at 72 weeks, with participants reporting substantially reduced hunger and increased fullness on validated appetite questionnaires 26. The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo, with early appetite reduction preceding the bulk of weight loss 27.

These agents are not FDA-approved specifically for polyphagia as a standalone symptom, but they address the underlying appetite dysregulation in obesity, type 2 diabetes, and increasingly in off-label hypothalamic obesity contexts. The appetite reduction typically begins within 1-2 weeks of starting therapy, often before meaningful weight loss occurs, confirming the central mechanism.

For patients whose increased appetite stems from an identifiable medical cause, the first step is always diagnosis and targeted treatment. GLP-1 receptor agonists fill a specific role when appetite dysregulation persists despite treating the primary condition, or when the primary condition itself (type 2 diabetes, obesity) responds to this drug class. A fasting glucose, HbA1c, and TSH, drawn at a single visit, can rule in or rule out the two most common endocrine causes in under 48 hours.